ASK REDCHAT ANYTHING ABOUT AKEBIA THERAPEUTICS, INC.
Akebia Therapeutics, Inc. (NASDAQ: AKBA)
Listen to this Section
$1.30
+0.0150
(
+1.17% )
1.0M
Sign up for The Small Stocks Big Money Newsletter and receive free small-cap news and insights.
Clinical Trial Pipeline Stages
| Drug Name |
Stage |
| Auryxia (ferric citrate)DetailsChronic kidney disease, Anemia, Kidney disease, Hyperphosphatemia |
Approved |
| Vafseo™ (Vadadustat)DetailsChronic kidney disease, Anemia, Kidney disease |
Approved |
Market Data
|
| Open |
$1.30 |
| Previous Close |
$1.28 |
| Volume |
1.0M |
| Market Cap |
$343.37M |
| Day Range |
$1.27 - $1.33 |
| 52 Week Range |
$0.82 - $4.04 |
| Shares Outstanding |
268.26M |
| Change % |
+1.17% |
| Net Change |
▲ 0.0150 |
| Insider Ownership |
N/A |
| Exchange |
NASDAQ |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| IPO Year | 2014 |
| Country | United States |
| Underwriter | IPO Intelligence Only |
Insider Ownership Transactions
Total Amount Purchased:
-2,547,335.00
| Date |
Type |
Amount Purchased |
Purchaser |
| 2024-02-02 |
Sale |
-149300.00 |
Hadas Nicole R. |
| 2024-02-02 |
Sale |
-149300.00 |
Snow Ellen |
| 2024-02-02 |
Sale |
-149300.00 |
Dahan Michel |
| 2024-02-02 |
Sale |
-223950.00 |
Malabre Richard C |
| 2024-02-02 |
Sale |
-303300.00 |
Grund Nicholas |
| 2024-02-02 |
Sale |
-202200.00 |
Burke Steven Keith |